baicalein-7-o-glucoside and Prediabetic-State

baicalein-7-o-glucoside has been researched along with Prediabetic-State* in 1 studies

Other Studies

1 other study(ies) available for baicalein-7-o-glucoside and Prediabetic-State

Article	Year
Oroxin A from Oroxylum indicum prevents the progression from prediabetes to diabetes in streptozotocin and high-fat diet induced mice. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2018, Jan-01, Volume: 38 Oroxylum indicum (L.) Kurz (Bignoniaceae) has been widely used for the treatment of respiratory infections and gastrointestinal disorders. Our previous study showed that an ethanol-water O. indicum seed extract (OISE), when combined with acarbose, reduced the risk of diabetes by 75% and effectively prevented the associated complications. Oroxin A, a major component of OISE, can activate PPARγ and inhibit α-glucosidase and it represents a promising candidate for diabetes intervention.. The aim of this study is to investigate the effect of oroxin A from O. indicum on the progression of prediabetes to diabetes and the underlying mechanisms in streptozotocin and high-fat-diet induced prediabetic mice.. Oroxin A was purified from OISE and its PPARγ transcriptional activation was determined in vitro and in vivo. The prediabetic mice were established by high-fat diet and streptozotocin, which was followed by treatment with oroxin A. The effect of oroxin A was determined by analysis of the lipid profiles, oxidative stress, hepatic function and histology. The mechanism of oroxin A was also investigated.. Oroxin A is a compound with low toxicity that has reduced the relative risk of progression from prediabetes to diabetes by 66.7% without inducing weight gain or hepatotoxicity. Oroxin A also improved the complications of prediabetes, such as lipid metabolism dysfunction and liver injury. Results of mechanism studies suggested that oroxin A is a partial PPARγ agonist that can activate PPARγ transcriptional activation in vitro and in vivo. Oroxin A also exhibited an inhibitory activity against α-glucosidase and an antioxidant capacity.. Oroxin A prevents the progression from prediabetes to diabetes through a multi-pathway intervention mechanism. Topics: alpha-Glucosidases; Animals; Antioxidants; Bignoniaceae; Diabetes Mellitus, Experimental; Diet, High-Fat; Flavones; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Lipid Metabolism; Liver; Male; Mice; Oxidative Stress; PPAR gamma; Prediabetic State; Seeds; Streptozocin	2018

Article

Year

Oroxin A from Oroxylum indicum prevents the progression from prediabetes to diabetes in streptozotocin and high-fat diet induced mice.

Phytomedicine : international journal of phytotherapy and phytopharmacology, 2018, Jan-01, Volume: 38

Oroxylum indicum (L.) Kurz (Bignoniaceae) has been widely used for the treatment of respiratory infections and gastrointestinal disorders. Our previous study showed that an ethanol-water O. indicum seed extract (OISE), when combined with acarbose, reduced the risk of diabetes by 75% and effectively prevented the associated complications. Oroxin A, a major component of OISE, can activate PPARγ and inhibit α-glucosidase and it represents a promising candidate for diabetes intervention.. The aim of this study is to investigate the effect of oroxin A from O. indicum on the progression of prediabetes to diabetes and the underlying mechanisms in streptozotocin and high-fat-diet induced prediabetic mice.. Oroxin A was purified from OISE and its PPARγ transcriptional activation was determined in vitro and in vivo. The prediabetic mice were established by high-fat diet and streptozotocin, which was followed by treatment with oroxin A. The effect of oroxin A was determined by analysis of the lipid profiles, oxidative stress, hepatic function and histology. The mechanism of oroxin A was also investigated.. Oroxin A is a compound with low toxicity that has reduced the relative risk of progression from prediabetes to diabetes by 66.7% without inducing weight gain or hepatotoxicity. Oroxin A also improved the complications of prediabetes, such as lipid metabolism dysfunction and liver injury. Results of mechanism studies suggested that oroxin A is a partial PPARγ agonist that can activate PPARγ transcriptional activation in vitro and in vivo. Oroxin A also exhibited an inhibitory activity against α-glucosidase and an antioxidant capacity.. Oroxin A prevents the progression from prediabetes to diabetes through a multi-pathway intervention mechanism.

Topics: alpha-Glucosidases; Animals; Antioxidants; Bignoniaceae; Diabetes Mellitus, Experimental; Diet, High-Fat; Flavones; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Lipid Metabolism; Liver; Male; Mice; Oxidative Stress; PPAR gamma; Prediabetic State; Seeds; Streptozocin

2018